Rhumbline Advisers Sells 40,756 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Rhumbline Advisers cut its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 35.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,269 shares of the biotechnology company's stock after selling 40,756 shares during the quarter. Rhumbline Advisers owned 0.15% of REGENXBIO worth $574,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RGNX. Barclays PLC lifted its position in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in REGENXBIO by 602.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after purchasing an additional 17,533 shares during the period. FMR LLC raised its position in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after purchasing an additional 17,563 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RGNX shares. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday. Morgan Stanley reiterated an "overweight" rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. Finally, The Goldman Sachs Group downgraded REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of "Moderate Buy" and an average price target of $33.88.

REGENXBIO Trading Up 1.7 %

NASDAQ RGNX traded up $0.10 during trading hours on Tuesday, hitting $6.11. 772,574 shares of the company's stock were exchanged, compared to its average volume of 936,634. The firm has a market cap of $302.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.35. The stock has a 50-day simple moving average of $7.42 and a 200 day simple moving average of $9.15. REGENXBIO Inc. has a 1-year low of $5.62 and a 1-year high of $23.33.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.